Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-World Study of Extended-Release Methylphenidate Suspension in Children with ADHD in Fujian
ChiCTR2600121197Phase 4Not yet recruiting
- Sponsor
- Fujian Children's Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylphenidate in attention deficit hyperactivity disorder (ADHD), sponsored by Fujian Children's Hospital. Primary endpoint: Proportion of patients with ≥40% reduction in SNAP-IV total score. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
methylphenidate
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on ChiCTR2600121197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121197.